Sutro Biopharma (STRO) EPS (Weighted Average and Diluted) (2019 - 2025)
Sutro Biopharma recorded quarterly EPS (Weighted Average and Diluted) of -$20.78 in Q4 2025, down 3001.49% quarter-over-quarter from -$0.67 in Q3 2025, and up 23.97% year-over-year from -$16.76 in Q4 2024.
Sutro Biopharma's EPS (Weighted Average and Diluted) history runs 7 years deep, the most recent figure standing at -$20.78 for Q4 2025.
- In Q4 2025, EPS (Weighted Average and Diluted) rose 23.97% year-over-year to -$20.78; the TTM figure through Dec 2025 stood at -$22.5 (up 22.68% YoY), while the FY2025 annual figure was -$22.49, up 23.5% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$20.78 for Q4 2025 at Sutro Biopharma, down from -$0.67 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.52 in Q4 2023 to a low of -$27.33 in Q4 2024.
- A 5-year average of -$3.02 and a median of -$0.64 in 2023 frame the typical range for EPS (Weighted Average and Diluted).
- Across the five-year window, EPS (Weighted Average and Diluted) soared 185.25% in 2023 and slumped 5355.77% in 2024, its largest moves.
- Sutro Biopharma's EPS (Weighted Average and Diluted) stood at -$0.83 in 2021, then gained by 26.51% to -$0.61 in 2022, then jumped by 185.25% to $0.52 in 2023, then plunged by 5355.77% to -$27.33 in 2024, then increased by 23.97% to -$20.78 in 2025.
- According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods registered -$20.78, -$0.67, and -$0.14 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.51 |
| 10 | Sutro Biopharma | 248.39 Mn | 248.39 Mn | - | -20.78 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -20.78 |
| Sep 30, 2025 | -0.67 |
| Jun 30, 2025 | -0.14 |
| Mar 31, 2025 | -0.91 |
| Dec 31, 2024 | -27.33 |
| Sep 30, 2024 | -0.59 |
| Jun 30, 2024 | -0.59 |
| Mar 31, 2024 | -0.59 |
| Dec 31, 2023 | 0.52 |
| Sep 30, 2023 | -0.81 |
| Jun 30, 2023 | -0.64 |
| Mar 31, 2023 | -0.85 |
| Dec 31, 2022 | -0.61 |
| Sep 30, 2022 | -0.37 |
| Jun 30, 2022 | -0.55 |
| Mar 31, 2022 | -0.84 |
| Dec 31, 2021 | -0.83 |
| Sep 30, 2021 | -0.67 |
| Jun 30, 2021 | -0.13 |
| Dec 31, 2020 | -1.89 |
| Sep 30, 2020 | 0.45 |
| Jun 30, 2020 | 0.94 |
| Sep 30, 2019 | -0.56 |
| Jun 30, 2019 | -0.60 |